Anxiety disorders are one of the most commonly co-occurring psychiatric diagnoses in youth with autism spectrum disorder (ASD), with a frequency ranging from 22% to 84%.
Methods:
We conducted a chart review of 29 children and adolescents with ASD who had been treated with selective serotonin reuptake inhibitor (SSRI) monotherapy for an anxiety disorder for at least 2 months. Subsequent chart reviews were conducted for the first follow-up visit within 2–6 months (M = 4.2 months) and the visit closest to 9 months posttreatment (ranging from 7 to 12 months; M = 10.5 months). The presence of adverse events (AEs) was examined, and a consensus Clinical Global Impressions Improvement (CGI-I) score was determined.
Results:
Fifty-five percent of patients were given a CGI-I of “improved” or “very much improved” at the 9-month follow-up. Four patients discontinued treatment owing to AEs. Other reported AEs not leading to discontinuation included vivid dreaming, increased emotional lability, and irritability. Responders included a number of patients who had failed previous SSRI trials.
Conclusions:
This study suggests that SSRI treatment should be considered for individuals with ASD and anxiety disorders, even if prior SSRI trials have been unsuccessful.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (4th ed.). Arlington, VA, American Psychiatric Association, 2000.
3.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Arlington, VA, American Psychiatric Publishing, 2013.
4.
Autism Speaks. Autism Speaks announces results reported for the Study of Fluoxetine in Autism (SOFIA): First industry-sponsored trial for the Autism Clinical Trials Network (ACTN) [Press release]. February 18, 2009.
5.
CathDC, RanN, SmitJH, BalkomAJ, ComijsHC: Symptom overlap between autism spectrum disorder, generalized social anxiety disorder and obsessive-compulsive disorder in adults: A preliminary case-controlled study. Psychopathology, 41:101–110, 2008.
6.
CouturierJL, NicolsonR: A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol, 12:243–248, 2002.
7.
de BruinEI, FerdinandRF, MeesterS, de NijsPF, VerheijF: High rates of psychiatric comorbidity in PDD-NOS. J Autism Dev Disord, 37:877–886, 2007.
8.
DelongGR, RitchCR, BurchS: Fluoxetine response in children with autistic spectrum disorders: Correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol, 44:652–659, 2002.
9.
ElsabbaghM, DivanG, KohYJ, KimYS, KauchaliS, MarcínC, Montiel-NavaC, PatelV, PaulaCS, WangC, YasamyMT, FombonneE: Global prevalence of autism and other pervasive developmental disorders. Autism Res, 5:160–179, 2012.
10.
GoodmanWK, PriceLH, RasmussenSA, MazureC, FleischmannRL, HillCL, HeningerGR, CharneyDS: The Yale-Brown obsessive compulsive scale. Arch Gen Psychiatry, 46:1006–1011, 1989.
11.
GuyW: ECDEU Assessment Manual of Psychopharmacology. Rockville, MD, United States Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976, pp 76–338.
12.
HenryCA, ShervinD, NeumeyerA, SteingardR, SpybrookJ, ChoueiriR, BaumanM: Retrial of selective serotonin reuptake inhibitors in children with pervasive developmental disorders: A retrospective chart review. J Child Adolesc Psychopharmacol, 19:111–117, 2009.
13.
HenryCA, SteingardR, VenterJ, GuptillJ, HalpernEF, BaumanM: Treatment outcome and outcome associations in children with pervasive developmental disorders treated with selective serotonin reuptake inhibitors: A chart review. J Child Adolesc Psychopharmacol, 16:187–195, 2006.
14.
HollanderE, PhillipsA, ChaplinW, ZagurskyK, NovotnyS, WassermanS, IyengarR: A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology, 30:582–589, 2005.
15.
HollanderE, SooryaL, ChaplinW, AnagnostouE, TaylorBP, FerrettiC, WassermanS, SettipaniC: A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. Am J Psychiatry, 169:292–299, 2012.
16.
HollanderE, SooryaL, WassermanS, EspositoK, ChaplinW, AnagnostouE: Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol, 9:209–213, 2006.
17.
KingBH, HollanderE, SikichL, McCrackenJT, ScahillL, BregmanJD, DonnellyCL, AnagnostouE, DukesK, SullivanL, HirtzD, WagnerA, Ritz L; STAART PsychopharmacologyNetwork: Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Arch Gen Psychiatry, 66:583–590, 2009.
18.
MartinA, KoenigK, AndersonGM, ScahillL: Low-dose fluvoxamine treatment in children and adolescents with pervasive developmental disorders: A prospective, open-label study. J Autism Dev Disord, 33:77–85, 2003.
19.
McDougleCJ, KreschLE, PoseyDJ: Repetitive thoughts and behaviors in pervasive developmental disorders: Treatment with serotonin reuptake inhibitors. J Autism Dev Disord, 30:427–435, 2000.
20.
McDougleCJ, NaylorST, CohenDJ, VolkmarFR, HenningerGR, PriceLH: A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry, 53:1001–1008, 1996.
21.
McDougleCJ, PoseyDJ, PotenzaMN: Neurobiology of serotonin function in autism. In: Autism Spectrum Disorders. Edited by HollanderE, New York, Marcel Dekker, 2003, pp. 199–220.
22.
MohattJW, KellerAE, WalkupJT: Psychopharmacology of pediatric anxiety disorders. In: Pediatric Anxiety Disorders. Edited by VasaRA, Roy AK. New York, NY, Springer Publishing, 2013, pp. 289–314.
23.
NamerowLB, ThomasP, BosticJQ, PrinceJ, MonuteauxMC: Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr, 24:104–108, 2003.
24.
PotenzaM, McDougleC: The role of serotonin in autism-spectrum disorders. CNS Spectrums, 2:25–42, 1997.
25.
SimonoffE, PicklesA, CharmanT, ChandlerS, LoucasT, BairdG: Psychiatric disorders in children with autism spectrum disorders: Prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry, 47:921–929, 2008.
26.
van SteenselFJ, BögelsSM, PerrinS: Anxiety disorders in children and adolescents with autistic spectrum disorders: A meta-analysis. Clin Child Fam Psychol Rev, 14:302–317, 2011.
27.
VasaRA, CarrollLM, NozzolilloAA, MahajanR, MazurekMO, BennettAE, WinkLK, BernalMP: A systematic review of treatments for anxiety in youth with autism spectrum disorders. J Autism Dev Disord, 44:3215–3229, 2014.
28.
VasaRA, MazurekMO, MahajanR, BennettAE, BernalMP, NozzolilloAA, ArnoldLE, CouryDL: Assessment and treatment of anxiety in youth with autism spectrum disorders. Pediatrics, 137:115–123, 2016.
29.
WhiteSW, OswaldD, OllendickT, ScahillL: Anxiety in children and adolescents with autism spectrum disorders. Clin Psychol Rev, 29:216–229, 2009.
